Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Earnings for Ligand Pharmaceuticals Incorporated (LGND)
Earnings in 2023 (TTM): $63.66 M
According to Ligand Pharmaceuticals Incorporated's latest financial reports the company's current earnings (TTM) are $63.66 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Ligand Pharmaceuticals Incorporated
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $63.66 M | $52.15 M |
| 2022 | $36.01 M | $-5,219,000 |
| 2021 | $47.3 M | $57.14 M |
| 2020 | $-10,538,000 | $-2,985,000 |
| 2019 | $796.64 M | $629.3 M |
| 2018 | $173.33 M | $143.32 M |
| 2017 | $57.23 M | $12.56 M |
| 2016 | $7.96 M | $-1,636,000 |
| 2015 | $35.33 M | $257.31 M |
| 2014 | $11.3 M | $12.02 M |
| 2013 | $9.21 M | $11.42 M |
| 2012 | $-3,865,000 | $-527,000 |
| 2011 | $-2,930,000 | $10.18 M |
| 2010 | $-15,403,000 | $-12,515,000 |
| 2009 | $-9,872,000 | $-1,948,000 |
| 2008 | $-97,515,000 | $-98,114,000 |
| 2007 | $-53,456,000 | $281.69 M |
| 2006 | $-174,273,000 | $-31,743,000 |
| 2005 | $36.34 M | $-36,399,000 |
| 2004 | $-44,908,000 | $-45,141,000 |
| 2003 | $-37,462,000 | $-37,462,000 |
| 2002 | $-32,596,000 | $-32,596,000 |
| 2001 | $-31,500,000 | $-42,995,000 |
| 2000 | $-46,707,000 | $-72,376,000 |
| 1999 | $-62,000,000 | $-74,700,000 |
| 1998 | $-112,600,000 | $-117,900,000 |
| 1997 | $-92,100,000 | $-100,200,000 |
| 1996 | $-29,200,000 | $-37,300,000 |
| 1995 | $-58,700,000 | $-64,200,000 |
| 1994 | $-26,400,000 | $-27,100,000 |